CONFERENCE
Date: December 06-07, 2012
City: Berlin, Germany
Event type: Round Table
REGISTER NOW
|
|
The Assessment Group
The Assessment Group is an independent assessment services company. The mission of The Assessment Group is to provide practice pattern assessments for healthcare industry marketing initiatives, and to evaluate the impact of promotional activities on practice.The company is exclusively dedicated to providing high-quality, objective, and effective assessments through both syndicated and custom reports for industry promotional and marketing initiatives.
The reports by The Assessment Group will help identify current physician practice patterns, understand differences in clinical decisions and the factors that influence those decisions, barriers to optimal patient care, and will provide actionable data for developing marketing strategies.
US Oncologist Survey: Optimizing Treatment for Advanced Non-Hodgkin's Lymphoma
Apr, 2011 · 61 pages
|
US$ 8,900.00 |
US Oncologist Survey: Optimizing Treatment for Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
Apr, 2011 · 26 pages
|
US$ 2,999.00 |
US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma
Apr, 2011 · 35 pages
|
US$ 2,999.00 |
US Oncologist Survey: Optimizing Treatment for Stage IIIA Asymptomatic Indolent Lymphoma
Apr, 2011 · 28 pages
|
US$ 2,999.00 |
US Oncologist Survey: Optimizing Treatment for Advanced Lung Cancer
Apr, 2011 · 56 pages
|
US$ 8,900.00 |
Advanced Lung Cancer in Patient Light Smoker with Lung Adenocarcinoma: Clinical Insights from a US Oncologists' Survey
Apr, 2011 · 28 pages
|
US$ 2,999.00 |
Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma: Clinical Insights from a US Oncologists' Survey
Apr, 2011 · 33 pages
|
US$ 2,999.00 |
Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey
Apr, 2011 · 25 pages
|
US$ 2,999.00 |
Castration Resistant Prostate Cancer: Clinical Insights from a US Oncologists' Survey
Mar, 2011 · 24 pages
|
US$ 2,999.00 |
Advanced Prostate Cancer with Increased PSA and Adenocarcinoma: Clinical Insights from a US Oncologists' Survey
Mar, 2011 · 35 pages
|
US$ 2,999.00 |
US Oncologist Survey: Optimizing Treatment for Advanced Prostate Cancer
Mar, 2011 · 52 pages
|
US$ 8,900.00 |
US Oncologist Survey: Optimizing Treatment for Metastatic Clear Cell Renal Cell Carcinoma
Feb, 2011 · 29 pages
|
US$ 2,499.00 |
US Oncologist Survey: Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer
Jan, 2011 · 31 pages
|
US$ 2,999.00 |
Triple Positive Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey
Jan, 2011 · 30 pages
|
US$ 2,999.00 |
Triple Negative Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey
Jan, 2011 · 36 pages
|
US$ 2,999.00 |
Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer
Feb, 2011 · 59 pages
|
US$ 6,900.00 |
US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer
Jan, 2011 · 59 pages
|
US$ 8,900.00 |
|
|
